Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model

被引:11
作者
Brooks, DA [1 ]
Hopwood, JJ [1 ]
King, BM [1 ]
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, N Adelaide, SA 5006, Australia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 1998年 / 1407卷 / 02期
基金
英国医学研究理事会;
关键词
lysosomal storage disease; enzyme replacement therapy; treatment outcome; immune reaction; hypersensitivity; antibody;
D O I
10.1016/S0925-4439(98)00034-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immune responses to enzyme replacement therapy (ERT) have been reported and can result in a hypersensitivity/ anaphylactic reaction during or immediately after enzyme infusion. We have investigated the infusion of the lysosomal enzyme N-acetylgalactosamine 4-sulphatase (4-sulphatase) into immunized, high titre rats as a model of immune response to ERT. To simulate ERT, high and low titre rats were infused with different doses of radiolabelled recombinant human 4-sulphatase (H-3-rh4S). There was evidence of altered targeting, inactivation and degradation of 4-sulphatase in high titre (titre 1 024 000) compared to low titre (titre 64) rats. There was more 4-sulphatase enzyme activity detected in 5 mg/kg high titre rats when compared to 1 mg/kg high titre rats, suggesting that the antibodies could be saturable in vivo. However, the rats treated with 5 mg/kg H-3-rh4S all had clinical signs of hypersensitivity reactions to 4-sulphatase infusion. There were no apparent signs of adverse reactions in either the high titre 1 mg/kg rats or the low titre rats (1, 5 mg/kg). The high titre 5 mg/kg rats also had changes in H-3-rh4S distribution, with lower levels delivered to the liver and a marked increase in the level remaining in plasma, when compared to either 1 mg/kg high titre rats or low titre rats (1, 5 mg/kg). (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 28 条
[1]   DOSE-DEPENDENT RESPONSES TO MACROPHAGE-TARGETED GLUCOCEREBROSIDASE IN A CHILD WITH GAUCHER DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DOPPELT, SH ;
HILL, SC ;
HOLDER, CA ;
MANKIN, HJ ;
MURRAY, GJ ;
ZIRZOW, GC ;
PARKER, RI .
JOURNAL OF PEDIATRICS, 1992, 120 (02) :277-280
[2]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[3]  
Belmatoug Nadia, 1995, Seminars in Hematology, V32, P33
[4]  
BEUTLER E, 1991, BLOOD, V78, P1183
[5]   IMMUNOQUANTIFICATION OF THE LOW ABUNDANCE LYSOSOMAL-ENZYME N-ACETYLGALACTOSAMINE 4-SULFATASE [J].
BROOKS, DA ;
MCCOURT, PAG ;
GIBSON, GJ ;
HOPWOOD, JJ .
JOURNAL OF INHERITED METABOLIC DISEASE, 1990, 13 (01) :108-120
[6]   Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models [J].
Brooks, DA ;
King, BM ;
Crawley, AC ;
Byers, S ;
Hopwood, JJ .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1997, 1361 (02) :203-216
[7]   Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI [J].
Crawley, AC ;
Niedzielski, KH ;
Isaac, EL ;
Davey, RCA ;
Byers, S ;
Hopwood, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04) :651-662
[8]   Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome [J].
Crawley, AC ;
Brooks, DA ;
Muller, VJ ;
Petersen, BA ;
Isaac, EL ;
Bielicki, J ;
King, BM ;
Boulter, CD ;
Moore, AJ ;
Fazzalari, NL ;
Anson, DS ;
Byers, S ;
Hopwood, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (08) :1864-1873
[9]   SYNTHETIC SORBENTS FOR REMOVAL OF FACTOR-VIII INHIBITORS FROM HEMOPHILIC-A PLASMA [J].
DAHRI, L ;
BOISSONVIDAL, C ;
REGNAULT, V ;
MULLER, D ;
SULTAN, Y ;
STOLTZ, JF .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1995, 664 (01) :47-54
[10]   INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].
EHRENFORTH, S ;
KREUZ, W ;
SCHARRER, I ;
LINDE, R ;
FUNK, M ;
GUNGOR, T ;
KRACKHARDT, B ;
KORNHUBER, B .
LANCET, 1992, 339 (8793) :594-598